These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26186072)

  • 1. Niclosamide Analogs for Treatment of Ovarian Cancer.
    Walters Haygood CL; Arend RC; Gangrade A; Chettiar S; Regan N; Hassmann CJ; Li PK; Hidalgo B; Straughn JM; Buchsbaum DJ
    Int J Gynecol Cancer; 2015 Oct; 25(8):1377-85. PubMed ID: 26186072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
    Arend RC; Londoño-Joshi AI; Gangrade A; Katre AA; Kurpad C; Li Y; Samant RS; Li PK; Landen CN; Yang ES; Hidalgo B; Alvarez RD; Straughn JM; Forero A; Buchsbaum DJ
    Oncotarget; 2016 Dec; 7(52):86803-86815. PubMed ID: 27888804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
    Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
    Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calpain system protein expression and activity in ovarian cancer.
    Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
    Li M; Yin J; Mao N; Pan L
    Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
    Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
    Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
    Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
    Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
    Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
    Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
    Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
    Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
    Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
    Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.
    Innamaa A; Jackson L; Asher V; van Schalkwyk G; Warren A; Keightley A; Hay D; Bali A; Sowter H; Khan R
    Clin Transl Oncol; 2013 Nov; 15(11):910-8. PubMed ID: 23479219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
    Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R
    J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.
    Coosemans AN; Baert T; D'Heygere V; Wouters R; DE Laet L; VAN Hoylandt A; Thirion G; Ceusters J; Laenen A; Vandecaveye V; Vergote I
    Anticancer Res; 2019 Nov; 39(11):5953-5962. PubMed ID: 31704820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.